Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,349
datasets available to search
ShareScore release 0.9.0
Dataset results
2,349 results for “Gastric cancer”
Gastric cancer spheroid
<p>3D<em> in vitro</em> culture of gastric cancer cells stably transfected with a mEmerald vector that stains a membrane protein.</p> <p>Image acquired at Light-sheet microscope, 488 laser, Nikon Plan Fluor 10x NA 0.3, step size (voxel) of 5 um</p>
Comprehensive 16s rRNA sequencing and metabolomics to investigate the effect of anticancer bioactive peptides combined with oxaliplatin on gastric cancer
<p>背景: 胃癌的发生、发展与肠道菌群密切相关。既往研究发现抗癌生物活性肽(ACBP)与奥沙利铂(OXA)联合对胃癌有显着的治疗作用,但ACBP-OXA对肠道菌群的影响仍不清楚。</p><p><strong>Methods:</strong> We established a nude mouse model of ACBP-OXA combined therapy for gastric cancer, the diversity of gut microbiota and fecal metabolomics were studied, and the correlation between gut microbiota and metabolites was analyzed.</p><p><strong>Results: </strong>ACBP-OXA联合疗法对肠道菌群具有很强的调节作用。16s rRNA研究发现,在门中,ACBP-OXA处理后,厚壁菌门和拟杆菌门的相对丰度发生显着变化,厚壁菌门的相对丰度下降,拟杆菌门的相对丰度增加。属内,ACBP-OXA组中毛螺菌科NK4AB6组的相对丰度降低,odpribacter和拟杆菌属的相对丰度增加。ACBP组乳酸菌相对丰度增加,ACBP-OXA和OXA组葡萄球菌相对丰度下降。GO和KEGG研究发现联合治疗机制与代谢和免疫有关。通过代谢组学研究,本研究发现差异代谢物与Benzenoids、Ligans、neoligans、其中脂质和脂类大多参与酪氨酸代谢、不饱和脂肪酸生物合成、苯丙氨酸代谢α-生物过程。将代谢组学与16s rRNA长寿素相结合,发现氨基酸相关代谢物与Jetgalilicus、Staphylococcus、Proteiniphilum等细菌属相关。</p><p>结论: ACBP与ACBP-OXA联合治疗可能通过改变肠道菌群的分布多样性和菌群结构来改善和恢复胃癌裸鼠的肠道菌群,这可能是抑制胃癌发生、发展的关键。该研究为进一步研究ACBP-OXA在胃癌治疗中的应用提供了新的方向。</p>
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
ClinicalTrials.gov study NCT04014075. IPD Sharing: YES. Countries: 5. Publications: 2.
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
ClinicalTrials.gov study NCT03329690. IPD Sharing: YES. Countries: 2. Publications: 2.
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
ClinicalTrials.gov study NCT00680901. IPD Sharing: YES. Countries: 23. Publications: 2.
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
ClinicalTrials.gov study NCT01515748. IPD Sharing: YES. Countries: 1. Publications: 2.
INICIB- URP. DATASET GASTRIC CANCER HOSPITAL MARIA AUXILIADORA, LIMA , PERU , 2018-2020
<p>DATASET GASTRIC CANCER HOSPITAL MARIA AUXILIADORA, LIMA , PERU , 2018-2020 </p>
Gastric Residual Volume, Safety and Effectiveness of Drinking 250ml Glucose Solution 2-3 Hours before Surgery in Gastric Cancer Patients: A Multicenter, Single-blind, Randomized Controlled Trial
<p><strong>Supplementary Figure 1</strong></p> <p> </p> <p>A. Change of QUICKI level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p=0.004) was significant, but no significant differences were noted for group(P=0.600) or group*time(P=0.963).</p> <p>B. Change of Recovery Level of QUICKI after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that no significant differences were noted for group(P=0.600) ,time (P=0.235) or group×time(P=0.963).</p> <p>C. Change of WBC level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p<0.001) was significant, and no significant differences were noted for group(P=0.392) or group×time(P=0.314).</p> <p>D. Change of CRP level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p<0.001) was significant, but no significant differences were noted for group(P=0.312) or group × time(P=0.826).</p>
Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer
<p><span>STROBE Statement—Checklist of items that should be included in reports of <strong><em>case-control studies</em></strong> </span></p>
miRNA in Gastric Cancer
Open the record for dataset details and reuse information.
Detection of genetic alterations in gastric cancer patients from Saudi Arabia using comparative genomic hybridization (CGH)
<p>Abstract</p> <p>Background: The present study was conducted to discover genetic imbalances such as DNA copy number variations (CNVs) associated with gastric cancer (GC) and to examine their association with different genes involved in the process of gastric carcinogenesis in Saudi population. </p> <p>Methods: Formalin-fixed paraffin-embedded (FFPE) tissues samples from 33 gastric cancer patients and 15 normal gastric samples were collected. Early and late stages GC samples were genotyped and CNVs were assessed by using Illumina HumanOmni1-Quad v.1.0 BeadChip. </p> <p>Results: Copy number gains were more frequent than losses throughout all GC samples compared to normal tissue samples. The mean number of the altered chromosome per case was 64 for gains and 40 for losses, and the median aberration length was 679115bp for gains and 375889bp for losses. We identified 7 high copy gain, 52 gains, 14 losses, 32 homozygous losses, and 10 copy neutral LOHs (loss of heterozygosities). Copy number gains were frequently detected at 1p36.32, 1q12, 1q22, 2p11.1, 4q23-q25, 5p12-p11, 6p21.33, 9q12-q21.11, 12q11-q12, 14q32.33, 16p13.3, 17p13.1, 17q25.3, 19q13.32, and losses at 1p36.23, 1p36.32, 1p32.1, 1q44, 3q25.2, 6p22.1, 6p21.33, 8p11.22, 10q22.1, 12p11.22, 14q32.12 and 16q24.2. We also identified 2 monosomy at chromosome 14 and 22, 52 partially trisomy and 22 whole chromosome 4 neutral loss of heterozygosities at 13q14.2-q21.33, 5p15.2-p15.1, 5q11.2-q13.2, 5q33.1-q34 and 3p14.2-q13.12. Furthermore, 11 gains and 2 losses at 1p36.32 were detected for 11 different GC samples and this region has not been reported before in other populations. Statistical analysis confirms significant association of H. pylori infection with T4 stage of GC as compare to control and other stages.</p>
Prognostic value of a modified pathological staging system for gastric cancer based on the number of retrieved lymph nodes and metastatic lymph node ratio raw data
<p><span>Clinical data from the US Surveillance, Epidemiology, and End Results (SEER) Program from 2010-2015 (https://seer.cancer.gov/) was extracted and analyzed as training set, data from 2016-2017 was adopted as internal validation set. Data from The Cancer Genome Atlas Program (TCGA) (https://portal.gdc.cancer.gov/) and prognosis data from Gastrointestinal surgery Department, Third Affiliated Hospital of Sun Yat-sen University were applied as external validation sets. </span></p> <p><span>Screening criteria for gastric cancer cases were as follow: exclusion of cases with only autopsy or death certificate, cases where initial tumor location was not stomach, patients with stage 0 and stage IV, cases without radical surgery, non-adenocarcinoma cases, death cases within one month after operation, and cases with unknown lymph node information and AJCC TNM stage.</span></p> <p><span>The study analyzed various factors such as age of diagnosis (<50 years, 50-69 years, >69 years), gender, race (white, black, other), AJCC T stage (T1-T4b), AJCC TNM stage (I-III), primary tumor location (stomach body, antrum/pylorus, cardia/fundus, greater gastric recurve, lesser gastric recurve, overlapping area, NOS), Clinical features such as tumor size (≥5cm,<5cm, unknown), tumor grade (I-IV), chemotherapy, radiotherapy, number of lymph nodes retrieved and number of metastases, and lymph node positive rate. The populations of American Indian/Alaskan and Asian/Pacific Islander were classified as "other" due to small sample sizes. Tumor grade was also analyzed, with grades I-IV representing highly differentiated, moderately differentiated, poorly differentiated, and signed-ring cell carcinoma, respectively. Overall survival (OS) is the time from cancer diagnosis to death from any cause, while disease-specific survival (DSS) is the time from cancer diagnosis to death specifically due to the disease.</span></p> <p><strong><span> </span></strong></p>
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
ClinicalTrials.gov study NCT04099641. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
ClinicalTrials.gov study NCT04704934. IPD Sharing: YES. Countries: 24. Publications: 1.
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
ClinicalTrials.gov study NCT01130337. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
ClinicalTrials.gov study NCT00526669. IPD Sharing: Not stated. Countries: 6. Publications: 1.
A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
ClinicalTrials.gov study NCT01246960. IPD Sharing: Not stated. Countries: 1. Publications: 1.
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
ClinicalTrials.gov study NCT07018661. IPD Sharing: YES. Countries: 1. Publications: 1.
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
ClinicalTrials.gov study NCT01585987. IPD Sharing: Not stated. Countries: 12. Publications: 1.
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
ClinicalTrials.gov study NCT01041404. IPD Sharing: Not stated. Countries: 24. Publications: 4.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.